Veterinary Medicine Information website

Nobivac DHPPi Vet. lyophilisate and solvent for suspension for injection for dogs

Authorised
  • Canine parainfluenza virus, strain Cornell, Live
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine distemper virus, strain Onderstepoort, Live
  • Canine parvovirus, strain 154, Live
Download as PDF

Product identification

Medicine name:
Nobivac DHPPi Vet. lyophilisate and solvent for suspension for injection for dogs
Active substance:
  • Canine parainfluenza virus, strain Cornell, Live
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine distemper virus, strain Onderstepoort, Live
  • Canine parvovirus, strain 154, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain Cornell, Live
    316228.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan LPV3, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain Onderstepoort, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain 154, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Denmark
Available in:
  • Denmark
Package description:
  • 10 x 1 dose vials in a carton or plastic box
  • 25 x 1 dose vials in a carton or plastic box
  • 50 x 1 dose vials in carton or plastic box
  • 5 x 1 dose vials in a carton or plastic box

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Danish Medicines Agency
Authorisation number:
  • 19406
Date of authorisation status change:
Reference member state:
  • Denmark
Procedure number:
  • DK/V/0103/001
Concerned member states:
  • Norway
  • Slovenia

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Danish (PDF)
Published on: 10/12/2025
Download

PI.pdf

English (PDF)
Published on: 27/01/2022
Download